(Q46785598)

25 December 2017

title

The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size (English)

1 reference

25 December 2017

author name string

Sesti C

1

1 reference

25 December 2017

Florio V

2

1 reference

25 December 2017

Johnson EG

3

1 reference

25 December 2017

Kloner RA

4

1 reference

25 December 2017

publication date

20 July 2006

1 reference

25 December 2017

International Journal of Impotence Research

published in

1 reference

25 December 2017

volume

19

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

55-61

1 reference

25 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.ijir.3901497

exact match

0 references

cites work

Sexual dysfunction in the United States: prevalence and predictors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Erectile dysfunction in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Overview of phosphodiesterase 5 inhibition in erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Cardiovascular effects of tadalafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Cardiovascular effects of tadalafil in patients on common antihypertensive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Potency, selectivity, and consequences of nonselectivity of PDE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

The efficacy and safety of tadalafil: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

7 January 2021

Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

7 January 2021

Erectile dysfunction and sildenafil citrate and cardiologists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

7 January 2021

Blood flow measurements with radionuclide-labeled particles

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

7 January 2021

Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901497

7 January 2021

Identifiers

DOI

10.1038/SJ.IJIR.3901497

1 reference

25 December 2017

1 reference

25 December 2017